Table 1 Description of younger and older AML populations according to post-remission treatment arms.
From: Cost comparison of post-remission strategies in younger and older AML patients in France
AML patients 18–60 y | AML patients > 60 y | ||||||
|---|---|---|---|---|---|---|---|
HDAC-123 | HDAC-135 | p | SDAC | IDAC | p | ||
n = 83 | n = 141 | n = 271 | n = 69 | ||||
Center, n (%) | Toulouse | 36 (43.4) | 87 (71.7) | 0.009 | 143 (93.5) | 10 (6.5) | <0.001 |
Bordeaux | 47 (56.6) | 54 (38.3) | 128 (68.5) | 59 (31.5) | |||
Age, mean (sd) | 43.9 (11.2) | 45.1 (11.7) | 0.442 | 68.6 (4.9) | 64.9 (3.2) | <0.001 | |
Sex, n male (%) | 52 (62.7) | 68 (48.2) | 0.039 | 169 (62,2) | 39 (56) | 0.408 | |
Cytogenetic risk, n (%) | Favorable | 30 (36) | 37 (26.4) | 0.246 | 9 (3.3) | 12 (17.4) | <0.001 |
Intermediate | 43 (51.8) | 88 (62.4) | 232 (85.6) | 34 (49.3) | |||
Adverse | 10 (12) | 16 (11.3) | 30 (11.1) | 23 (33.3) | |||
N post-remissions session, n (%) | 1 | 11 (13) | 22 (15.6) | 0.281 | 47 (17.3) | 8 (11.6) | <0.001 |
2 | 31 (37.3) | 38 (27) | 48 (17.7) | 23 33.3) | |||
3 | 41 (49.4) | 81 (57.4) | 24 (8.9) | 38 (55.1) | |||
≥4 | 0 | 0 | 158 (58.3) | 0 | |||
Period length (days), mean (sd) | 85 (32) | 89 (35) | 0.357 | 159,1 (104) | 93,5 (50) | <0.001 | |
Allo-HSCT, n (%) | 5 (6) | 0 | 0.006 | 4 (1,48) | 2 (2,9) | 0.352 | |
Relapse or death during the study period, n (%) | 0 | 4 (5,6) | 0.299 | 17 (6.3) | 2 (2.9) | 0.385 | |
